News from shire plc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 15, 2014, 08:00 ET

Shire Announces FDA Acceptance for Filing with Priority Review of Supplemental New Drug Application (sNDA) for Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) for Adults with Binge Eating Disorder

Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announced today that the US Food and Drug Administration (FDA)...

Jul 23, 2014, 07:00 ET

Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen

Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, and ArmaGen, a US privately held biotechnology company, today...

Jul 18, 2014, 06:14 ET

Shire Delivers Record Quarterly Revenues and Non GAAP Diluted Earnings per ADS up 42%

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION...

Jul 17, 2014, 13:30 ET

Shire Reports Top-Line Results From Two Head-to-Head Studies Comparing Vyvanse® (lisdexamfetamine dimesylate), CII, With Concerta® (methylphenidate HCl), CII, in Adolescents with ADHD

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced top-line results from two Phase 4 efficacy and safety studies of Vyvanse®...

Jul 14, 2014, 02:34 ET

Shire plc: Update re: AbbVie Proposal

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION...

Jul 11, 2014, 14:00 ET

Shire plc - Statement re: Media Speculation

Not for release, publication or distribution (in whole or in part) in, into or from any jurisdiction where to do so would constitute a violation...

Jul 08, 2014, 09:44 ET

Shire plc - Statement re: AbbVie Announcement

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION...

Jun 30, 2014, 02:00 ET

Shire Receives US$248 Million Cash Refund From the Canadian Revenue Authorities, Expects a Further US$162 Million in Late 2014

Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPG) announces that its Canadian subsidiary(1) has received assessments from the Canadian...

Jun 25, 2014, 11:47 ET

Shire Comments on AbbVie's Unchanged Proposal

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION...

Jun 25, 2014, 02:44 ET

Vyvanse® Patents Found to Be Infringed and Valid by U.S. District Court

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Judge Stanley R. Chesler of the U.S. District Court for the District of New Jersey granted...

Jun 23, 2014, 07:33 ET

Shire plc: the Path to US$10 Billion in Product Sales by 2020

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION...

Jun 23, 2014, 02:00 ET

Shire to Host Investor Call

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION...

Jun 20, 2014, 13:39 ET

Shire Update Call for Investors

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION...

Jun 20, 2014, 04:22 ET

Shire Confirms Rejection of AbbVie Proposal

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION...

Jun 12, 2014, 09:00 ET

Shire Agrees to FDA Request to Conduct Clinical Trials Investigating the Potential Use of Vyvanse® (lisdexamfetamine dimesylate) in Preschool-Age Children with ADHD

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that it has agreed to a Written Request by the Food and Drug Administration (FDA) to conduct...

Jun 10, 2014, 09:30 ET

Shire to Participate at the Goldman Sachs 35th Annual Global Healthcare Conference

Shire's Chief Executive Officer, Flemming Ornskov, MD will participate at the Goldman Sachs 35th Annual Global Healthcare Conference on Thursday,...

Jun 02, 2014, 07:00 ET

Shire to Present at the Jefferies 2014 Global Healthcare Conference

Shire's Chief Executive Officer, Flemming Ornskov, MD will present at the Jefferies 2014 Global Healthcare Conference today, June 2nd at 9:30 am...

May 19, 2014, 02:00 ET

Shire Plans to Submit a New Drug Application to FDA for Lifitegrast for Dry Eye Disease in Adults

- FDA submission planned for 1st Quarter 2015  - Shire forms business unit focused in...

May 16, 2014, 11:43 ET

Shire Plans to Submit a New Drug Application to FDA for Lifitegrast for Dry Eye Disease in Adults

  - FDA submission planned for 1st Quarter 2015  - Shire forms business unit focused in ophthalmics  Following a...

May 12, 2014, 07:00 ET

Shire Adds to Rare Disease Portfolio with Acquisition of Lumena Pharmaceuticals, Bringing Late Stage Compounds for Rare GI/Hepatic Conditions

- Acquisition of Lumena Pharmaceuticals, a biopharmaceutical  company with late stage rare disease pipeline assets - Adds to...